Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
Immunofluorescent analysis of BcL-xL (green) in U-2 OS cells. Cells were fixed and permeabilized with ice-cold methanol for 10 minutes at room temperature, and blocked with 0.3% BSA in PBS for 1 hour at room temperature. Cells were probed with a BcL-xL monoclonal antibody (Product # MA5-11950) at a dilution of 1:20 (right panel), or incubated in blocking buffer as a negative control (left panel) overnight at 4°C. Cells were washed with PBS, and incubated with a DyLight 488 goat anti-mouse IgG secondary antibody (Product # 35502) at a dilution of 1:500 for 1 hour at room temperature. Nuclei (blue) were stained with DAPI (Product # 46190). Images were taken on a Thermo Scientific ToxInsight Instrument at 20X magnification.
|Tested species reactivity||Human, Mouse|
|Published species reactivity||Human, Mouse|
|Host / Isotype||Mouse / IgG2a|
|Immunogen||A synthetic peptide corresponding to aa 35-50 (TEAPEETEAERETPSA) of mouse Bcl-xL protein|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||1 ug/test|
|Immunohistochemistry (Paraffin) (IHC (P))||1:400|
|Immunoprecipitation (IP)||2-4 ug|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA5-11950 targets BCL-XL in FACS, IF, IHC (P) and IP applications.
MA5-11950 can be used to stain cells by IF following fixation/permeabilization in either methanol or 4% paraformaldehyde/0.5% octyl-beta-glucoside. The antibody can be used at a lower concentration when fixed and permeabilized by the latter method.
Bcl-X has two isoforms, Bcl-XL (long) a 241 amino acid protein and Bcl-XS (short) a 178 amino acid protein lacking a 63 amino acid domain that is well conserved among members of the Bcl-2 family. Bcl-XL represses cell death, while Bcl-XS favors cell death.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
New diagnostic markers in salivary gland tumors.
MA5-11950 was used in immunohistochemistry to study the expresion of tumor antigens in order to identify novel diagnostic markers of parotid gland tumors
|Schneider S,Kloimstein P,Pammer J,Brannath W,Grasl MCh,Erovic BM||European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery (271:1999)||2014|
Biomarkers in advanced larynx cancer.
MA5-11950 was used in immunohistochemistry to study the predictive and prognostic value of a range of biomarkers in pre-treatment biopsies from patients with advanced cancer of the larynx
|Bradford CR,Kumar B,Bellile E,Lee J,Taylor J,D'Silva N,Cordell K,Kleer C,Kupfer R,Kumar P,Urba S,Worden F,Eisbruch A,Wolf GT,Teknos TN,Prince ME,Chepeha DB,Hogikyan ND,Moyer JS,Carey TE||The Laryngoscope (124:179)||2014|
Identification of novel target proteins in sebaceous gland carcinoma.
MA5-11950 was used in immunohistochemistry to identify novel therapeutic target proteins in sebaceous gland carcinoma
|Erovic BM,Al Habeeb A,Harris L,Goldstein DP,Kim D,Ghazarian D,Irish JC||Head & neck (35:642)||2013|
Head and neck squamous cell carcinoma in pregnant women.
MA5-11950 was used in immunohistochemistry to study oral cancer in pregnant women
|Eliassen AM,Hauff SJ,Tang AL,Thomas DH,McHugh JB,Walline HM,Stoerker J,Maxwell JH,Worden FP,Eisbruch A,Czerwinski MJ,Papagerakis SM,Chepeha DB,Bradford CR,Hanauer DA,Carey TE,Prince ME||Head & neck (35:335)||2013|
Biomarkers of parathyroid carcinoma.
MA5-11950 was used in immunohistochemistry to establish a biomarker panel suitable for the identification of parathyroid carcinomas
|Erovic BM,Harris L,Jamali M,Goldstein DP,Irish JC,Asa SL,Mete O||Endocrine pathology (23:221)||2012|
Radiotherapy in laryngeal carcinoma: can a panel of 13 markers predict response?
MA5-11950 was used in immunohistochemistry to study the value of 13 immunohistochemical biomarkers in predicting response to radiotherapy in laryngeal cancer
|Wildeman MA,Gibcus JH,Hauptmann M,Begg AC,van Velthuysen ML,Hoebers FJ,Mastik MF,Schuuring E,van der Wal JE,van den Brekel MW||The Laryngoscope (119:316)||2009|
Expression of p53 and Bcl-xL as predictive markers for larynx preservation in advanced laryngeal cancer.
MA5-11950 was used in immunohistochemistry to examine the prognostic significance of p53 and Bcl-xL as predictive markers in advanced laryngeal cancer
|Kumar B,Cordell KG,D'Silva N,Prince ME,Adams ME,Fisher SG,Wolf GT,Carey TE,Bradford CR||Archives of otolaryngology--head & neck surgery (134:363)||2008|
Targeting apoptosis to overcome cisplatin resistance: a translational study in head and neck cancer.
MA5-11950 was used in immunohistochemistry to investigate the expression of Bcl-xL and p53 in cisplatin-resistant head and neck squamous cell cancers
|Bauer JA,Kumar B,Cordell KG,Prince ME,Tran HH,Wolf GT,Chepeha DB,Teknos TN,Wang S,Eisbruch A,Tsien CI,Urba SG,Worden FP,Lee J,Griffith KA,Taylor JM,D'Silva N,Wang SJ,Wolter KG,Henson B,Fisher SG,Carey TE,Bradford CR||International journal of radiation oncology, biology, physics (69:S106)||2007|
A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer.
MA5-11950 was used in immunohistochemistry to perform a phase I clinical study of oblimersen and irintecan in advanced metastatic colorectal cancer
|Mita MM,Ochoa L,Rowinsky EK,Kuhn J,Schwartz G,Hammond LA,Patnaik A,Yeh IT,Izbicka E,Berg K,Tolcher AW||Annals of oncology : official journal of the European Society for Medical Oncology / ESMO (17:313)||2006|
Bcl-2 expression predicts radiotherapy failure in laryngeal cancer.
MA5-11950 was used in immunohistochemistry to study the value of Bcl-2 expression in predicting the response to radiotherapy of laryngeal cancer patients
|Nix P,Cawkwell L,Patmore H,Greenman J,Stafford N||British journal of cancer (92:2185)||2005|
MyoD regulates apoptosis of myoblasts through microRNA-mediated down-regulation of Pax3.
MA5-11950 was used in western blot to study the mechanism by which the MyoD regulates myoblast apoptosis
|Hirai H,Verma M,Watanabe S,Tastad C,Asakura Y,Asakura A||The Journal of cell biology (191:347)||2010|
anti-apoptosis regulatory protein; apoptosis regulator Bcl-X; B-cell leukemia/lymphoma x; bcl-2-like protein 1; bcl2-L-1; BCL2-like 1; protein phosphatase 1, regulatory subunit 52
Bcl(X)L; Bcl-X; Bcl-XL; BCL-XL/S; bcl2-L-1; BCL2L; BCL2L1; BCLX; PPP1R52